Normal Cells

MUC1-N Physically Protects Cell Surface
MUC1-C is Activated in Response to Inflammation and Other Forms of Stress
MUC1 Overexpressed in ~900,000 Tumors Diagnosed Each Year in the US
Breast, NSCLC, Prostate, Ovarian, Pancreatic, Colon and Hematologic Malignancies

MUC1 Expression Increased 50-100x In Cancer Cells

MUC1 is Expressed in Solid Tumor and Leukemia Stem-like Cells

Targeting MUC1-C Overcomes Drug Resistance

Inhibition of MUC1-C Synergizes with Chemotherapeutics and Targeted Agents 

MUC1 Blocks Immune Recognition and Destruction

Cancer Cells

MUC1-N is shed from the tumor cell surface
MUC1-C Induces Proliferation

​MUC1-C Blocks Cell Death

Genus Oncology is Developing Multiple Approaches to Target the Non-Shed MUC1-C Subunit

​Early attempts at targeting MUC1, particularly with antibodies, focused on MUC1-N and were ineffective because this subunit is shed from the cancer cell surface.
Genus Programs Targeting the
​MUC1-C Cytoplastic Domain
Genus Programs Targeting the
​MUC1-C Extracellular Domain
  • ADC: Antibody-drug conjugate
  • ADCC: Antibody-dependent cell-mediated cytotoxicity
  • BsAb: Bispecific
  • CAR-T